media – Page 110 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

MedtecLIVE 2024

Organiser：Informa Time:18- 20 June 2024 address：Messepiazza 1, 70629 Stuttgart, Stuttgart Germany Exhibition hall: Messe Stuttgart Product range: Precision instruments: Specialized medical alloys, microprocessors, computer numerical control (CNC), ultrasound and laser technology, surgical equipment, interventional cardiac devices and medical accessories for surgical technology Medical plastics technology: medical classification of plastic raw materials, outsourcing and processing of medical consumables, packaging and drug delivery Automation equipment technology: automatic production process about automatic setting, assembly process and robot motion control Pharmaceutical packaging: Packaging solutions from filling processes to packaging materials and from disposable product manufacturers to outsourcers About MedtecLIVE： The German medical equipment and medical technology exhibition MedtecLIVE, the second largest exhibition in Europe’s medical technology field, is held once a year, covering the entire supply chain, and more than 400 medical suppliers from the global medical technology field present innovative products, solutions and services for distributors and equipment manufacturers. Discuss the most important ...
- Source: drugdu
- 193
- May 23, 2024
【EXPERT Q&A】How to apply for a medical device class III business license?

Drugdu.com expert’s response: To obtain a Class III Medical Device Operating License, you would need to follow a specific process and meet certain requirements. Here is a general outline of the steps in English: 1.Prepare Application Materials: Gather all necessary documents, including the “Application Form for Medical Device Operating License” (signed by the legal representative or stamped with the company seal), proof of identity, education, and appointment documents for the legal representative. Also, provide copies of the “Pre-Approval Notice for Enterprise Name” or “Business License” issued by the Administration for Industry and Commerce. Additionally, submit proof of property or lease agreements with the lessor’s property certificate, as well as layout plans of the business premises and warehouse. 2.Submit Application Materials: Submit the prepared application materials to the local Food and Drug Administration or Market Regulatory Department. 3.Review and Onsite Inspection: The local Food and Drug Administration or Market Regulatory Department ...
- Source: drugdu
- 133
- May 22, 2024
Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients

Stroke is the primary cause of disability globally and ranks as the second leading cause of death. However, timely early intervention can prevent severe outcomes. Most strokes are ischemic, resulting from a blockage that disrupts blood flow to the brain. Large vessel occlusion (LVO) strokes, a severe form of ischemic stroke, occur when a major artery in the brain is obstructed. The brain cells begin to die within minutes due to the deprivation of oxygen and nutrients. LVO strokes are critical emergencies that necessitate rapid treatment with mechanical thrombectomy, a procedure that removes the obstruction. Now, a new test combines blood-based biomarkers with a clinical score to accurately identify patients suffering from LVO strokes. Mechanical thrombectomy has revolutionized stroke treatment, potentially restoring individuals to full health as though they never experienced a stroke. The sooner this procedure is applied, the better the outcomes for patients. This groundbreaking technology, developed by ...
- Source: drugdu
- 82
- May 22, 2024
New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based profiling. DNA methylation functions as a regulatory mechanism to control gene activity, essentially turning genes on or off. However, the time required for such testing can be a significant hindrance, often taking several weeks—a delay that can be critical when patients need prompt decisions regarding their treatment. Additionally, these tests are not widely available in most hospitals around the world. Now, a new artificial intelligence (AI) tool has been developed to classify brain tumors more quickly and accurately. Researchers at The Australian National University (ANU, Canberra, Australia) have created DEPLOY. This new method predicts DNA methylation patterns to classify brain tumors into 10 major subtypes. DEPLOY utilizes histopathology images, which are microscopic images of patient tissue samples. The model was trained and ...
- Source: drugdu
- 74
- May 22, 2024
Coya Therapeutics Receives $5 Million Investment from the Alzheimer’s Drug Discovery Foundation

Don Tracy, Associate Editor Investment from the Alzheimer’s Drug Discovery Foundation (ADDF) aims to support the development of Coya 302, a therapeutic candidate for the treatment of frontotemporal dementia (FTD). Coya Therapeutics announced that it has received a $5 million strategic investment from the Alzheimer’s Drug Discovery Foundation (ADDF). According to the company, the investment consisted of 603,136 shares of stock at $8.29 per share. Coya intends to use the funding for supporting the development of Coya 302, its lead therapeutic candidate, mainly in an upcoming Phase II trial targeting frontotemporal dementia (FTD). Reportedly, the investment was made through a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, aiming to file a registration statement with the SEC for resale of the securities.1 “We are grateful that a world-renowned organization like the ADDF has chosen to support our corporate mission as well as the clinical ...
- Source: drugdu
- 70
- May 22, 2024
European Commission Decision Is a Reprieve for PTC Therapeutics’ Rare Muscle Disease Drug

The PTC Therapeutics drug Translarna failed its confirmatory study in Duchenne muscular dystrophy. Analysts say the European Commission’s decision to not adopt the Committee on Medicinal Products for Human Use’s negative opinion on the drug is unusual, if not unprecedented. By Frank VinluanA PTC Therapeutics drug that failed a confirmatory study in the rare muscle-wasting disorder Duchenne muscular dystrophy may remain on the market in Europe for now. Regulators there took the rare step of declining to adopt a recommendation opposing renewal of the product’s marketing authorization. The PTC drug, Translarna, received conditional marketing authorization in 2014 based on Phase 2 data. The conditional nature of this pathway requires a company to seek annual renewals of the authorization until it generates the clinical data that supports a standard marketing authorization. In a placebo-controlled Phase 3 study, Translarna failed to achieve the main goal of showing a significant change according to ...
- Source: drugdu
- 69
- May 22, 2024
Amgen and AstraZeneca ponder label expansion for Tezspire in COPD

Amgen and AstraZeneca have highlighted the potential of Tezspire (tezepelumab) in chronic obstructive pulmonary disease (COPD) in a subgroup of patients in a Phase IIb study even though the trial missed the primary endpoint. The therapy failed to show a significant reduction in the annual rate of moderate to severe exacerbations compared to the placebo, the trial’s primary endpoint. The data from the placebo-controlled Phase IIa COURSE trial (NCT04039113) was presented at the American Thoracic Society (ATS) International Conference taking place in San Diego, US, from 16 to 21 May. However, a pre-determined subgroup analysis of COPD patients based on the levels of eosinophils, measured as baseline eosinophil count (BEC), showed significant reductions in COPD exacerbations. The therapy also demonstrated a 48% reduction in severe exacerbations compared to the placebo. Patients who received Tezspire while having a BEC of 150 cells/μL or more, which is associated with increased COPD-related emergency ...
- Source: drugdu
- 70
- May 22, 2024
Chiatai Tianqing Participated in China Biologics Conference and Shared Recombinant Coagulation Factor Drug Development Achievements

On May 16-18, the “23rd China Biologics Conference (CBioPC 2024)” was held in Guangzhou. This is an academic event in the field of biomedicine in China. Zhong Nanshan, recipient of the Order of the Republic and academician of the Chinese Academy of Engineering, Zhang Hui, vice president of the China Academy of Food and Drug Administration, Zhao Bingxiang, general manager of China National Pharmaceutical Group Corporation, and Shao Jingbo, deputy director of Guangzhou Development District Administrative Committee, attended the opening ceremony and delivered speeches. Dr. Wei Zhao, Vice President of Chiatai Tianqing, was invited to attend the conference and introduced the company’s experience in pharmacological development of recombinant coagulation factor drugs. The theme of this conference is biopharmaceutical innovation and public health security, aiming to build biopharmaceutical science and technology capacity with core competitiveness and independent intellectual property rights, vigorously develop new productivity of biopharmaceuticals with Chinese characteristics, and actively ...
- Source: drugdu
- 74
- May 22, 2024
Glenmark launches the next phase of ‘India First Heart First’ Campaign

On World Hypertension Day 2024, the second phase of the ‘India First Heart First’ Campaign was launched. Glenmark collaborated with gemstone carver artist Prithviraj Kumawat to sculpt a monumental human heart from a single stone of Rose quartz, a stone associated with the heart chakra which promotes emotional balance. This sculpture, standing 8 feet tall and weighing 3.5 tons, was unveiled on May 17, 2024, and was attended by cardiologists from Delhi and Jaipur, including Dr Deepak Maheshwari, Dr J S Makkar, and Dr Manoj Kumar. The event featured talks from cardiologists Dr J S Hiremath, Dr A Sreenivas Kumar, Dr JPS Sawhney and Dr Dilip Kumar highlighting the importance of heart health. Mr Kumawat spoke about his journey of creating the gemstone sculpture. Reportedly, 35,000 doctors from across India sent in their pledges to support cardiovascular disease awareness. Their signed pledge cards were displayed at the base of the ...
- Source: drugdu
- 68
- May 22, 2024
GVSAP collaborates with Biocytogen

GV Safety Assessment Platform (GVSAP), an integrated R&D enabler offering comprehensive preclinical research solutions, recently announced a partnership with Biocytogen. This collaboration aims to boost the R&D endeavours of Indian researchers by democratising tools and technologies. According to a press release, through this alliance, Indian biomedical researchers will gain access to Biocytogen’s expertise in providing humanised research models, other off-the-shelf models and products, and Gene Targeting Services offered under Biocytogen’s sub-brand BioMice. https://www.expresspharma.in/gvsap-collaborates-with-biocytogen/
- Source: drugdu
- 68
- May 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.